• MJHLS Brand Logo

© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

Practice

Study: Biosimilar Filgrastim Use Is Concordant With EORTC Guidelines

November 21st 2018

By Kelly Davio

Article

Some studies have found that granulocyte colony-stimulating factor (G-CSF) therapies are underused for the prophylaxis of febrile neutropenia (FN) in Europe, but the widespread availability of cheaper biosimilar options has led to increased use. A new study, published in BMC Cancer, sought to examine the use of the biosimilar filgrastim, Zarzio, in relationship to European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

Asian Gastroenterologists Are Less Confident in Biosimilars Than Their European Peers

November 20th 2018

By The Center for Biosimilars Staff

Article

Results of a recent survey demonstrate that Asian physicians are less confident in using biosimilars than their European peers are.

Dose Escalation of Adalimumab Can Overcome Loss of Response in CD

November 19th 2018

By Kelly Davio

Article

In many regulatory territories, patients with Crohn disease (CD) who lose response to adalimumab at a dose of 40 mg given every other week may be given an escalation to 40 mg every week. However, in Japan, where adalimumab is typically administered by a healthcare provider rather than by the patient, a study investigated the efficacy, safety, and pharmacokinetics (PK) of adalimumab after a dose escalation to 80 mg every other week as a means to reduce the need for additional patient appointments.

More UK Evidence Documents Successful Switching to Biosimilar Infliximab

November 19th 2018

By Kelly Davio

Article

During the 83rd Annual Scientific Meeting of the American College of Gastroenterology, researchers from the United Kingdom reported on yet another large, nonmedical switch from reference infliximab to biosimilar CT-P13 (Inflectra, Remsima), this time in the Pennine Acute Hospitals Trust.

Quantification Assays Optimized for Remicade Can Be Used to Monitor Biosimilar Flixabi

November 16th 2018

By Jackie Syrop

Article

Three quantification assays optimized for therapeutic drug monitoring of Remicade can be used to monitor levels of the infliximab biosimilar Flixabi (sold in the United States as Renflexis).

Research Underscores Rituximab's Utility in Treating MS

November 15th 2018

By Jackie Syrop

Article

Rituximab is frequently used off-label as a treatment for relapsing-remitting multiple sclerosis (MS) because it induces the depletion of circulating B-cell and T-cell lymphocytes and targets CD20 protein in B cells that are responsible for the production of antibodies.

Does Biosimilar Infliximab Have a Role After Secondary Loss of Response to Its Reference?

November 15th 2018

By Jackie Syrop

Article

Results of a small Greek observational study suggest that biosimilar infliximab may be an effective alternative for the treatment of patients with inflammatory bowel disease (IBD) who have active disease and experienced a loss of response to innovator infliximab (Remicade).

US Drug Prescription Rates Influenced by Race, State Healthcare Laws, and Wealth

November 14th 2018

By Jackie Syrop

Article

The best predictors of which US counties’ patients are most likely to be prescribed higher-priced drugs are income, healthcare costs, and access to exercise opportunities, according to a new study published online in Nature Communications.

First-Line Bevacizumab More Effective in MBC Not Previously Treated with Taxanes

November 14th 2018

By Jackie Syrop

Article

Among long-term responders, first-line bevacizumab-based therapy is more effective in patients with HER2-negative metastatic breast cancer (MBC) who were not previously treated with taxanes, a recent Spanish study suggests.

Research Demonstrates Biosimilars' Increasing Role in Cancer Treatment

November 13th 2018

By Kelly Davio

Article

During this week’s International Society for Pharmacoeconomics and Outcomes Research 2018 European meeting, the role of biosimilars in oncology is the subject of several research presentations, all of which underscore the importance of these agents in increasing patient access and driving down costs.